secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001493152-24-015859
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.03, 2.01, 3.02, 3.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mangoceuticals acquires patent portfolio for $20M; issues Series C Preferred, eyes Nasdaq compliance
--------------------------------------------------------------------------------

- Acquired global patent portfolio from Intramont for $20M: 980k Series C Preferred Shares ($19.6M) plus $400k cash over 7 months.
- Patents cover preventive oral solutions for cold, respiratory diseases, HPV; plans ODT, toothpaste, mouthwash products.
- Series C Preferred: 6% cumulative dividend, $20 stated value, convertible at $10.00/share (2-for-1), with 4.999% conversion cap.
- Grant-back license to Intramont with 10% royalty on gross worldwide sales beginning April 2025.
- Company believes stockholders' equity now >$5M, regaining Nasdaq minimum equity requirement; still non-compliant on bid price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315224015859/0001493152-24-015859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315224015859/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-015859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer